ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
2 announcements with these filters
Sudarshan Pharma stated its proposed 9.50% stake acquisition of Med Therapy Biotechnology Inc. remains under due diligence. Promoter acquisitions of 1.50% each are also pending.
Sudarshan Pharma Industries will acquire a 9.50% stake in MedTherapy Biotechnology Inc. for cash. Its promoters will separately acquire an additional 3% combined stake.